G1 Therapeutics Inc. (GTHX)

57.42 -0.33 (-0.571%)

IEX Real-Time Price

August 17, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 57.75

Price Open 57.61

Volume: 88,953

Avg Volume: 253,130

Market Cap: 1.92B

P/E Ratio -23.06

52 Wk Range 15.78-64.83



GTHX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
32.96M
2.6M
9.92
7.88%

2018-07-13
32.26M
2.81M
6.51
8.72%

2018-06-29
32.26M
2.95M
5.85
9.13%

2018-06-15
32.27M
1.92M
4.40
5.95%




GTHX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-08
Q2 2018
AMC
-0.66 (4)
-0.64
0.02

2018-05-16
Q1 2018
N/A
-0.64 (3)
0.00
0.00

2018-05-03
Q1 2018
N/A
-0.64 (3)
-0.70
-0.06

2018-02-21
Q4 2017
AMC
-0.58 (3)
-0.60
-0.02

News

G1 Therapeutics (GTHX) CEO Mark Velleca on Q2 2018 Results - Earnings Call Transcript (2018-08-11 00:21 SeekingAlpha)

G1 Therapeutics (GTHX) Q2 2018 Results Earnings Conference Call August 8, 2018, 04:30 PM ET Executives Jeff Macdonald - IR Mark Velleca - CEO Buck Phillips - CFO and SVP, Corporate Development Raj Malik - Chief Medical Officer, SVP, R&D Analysts Chris Shibutani - Cowe…

 


Statistics

Shares Outstanding: 33.4M

Top 15 Institution Percent: 64.90

Price To Sales: N/A

Price To Book: 10.87

Revenue: N/A

Gross Profit: N/A

Cash: 118.38M

Debt: N/A

Return On Assets: -45.49

Return On Equity: -49.21

Profit Margin: N/A

Price History

Beta: -1.58

50-day Moving Avg: 48.18

200-day Moving Avg: 34.40

YTD Change: 180.23

5-day Change: 1.95

1-month Change: 25.95

3-month Change: 18.86

6-month Change: 200.00

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: G1 Therapeutics Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.g1therapeutics.com

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It engages in developing novel, small-molecule therapies to target significant unmet needs to treat cancer.